eClinical Technology and Industy News

Samsung Receives FDA Clearance for AI Algorithms that Detect Lung Nodules in Chest X-rays

Chest radiograph without Auto Lung Nodule Detection (ALND) and chest radiograph with lung nodule marked. (Photo: Business Wire)

Excerpt from the Press Release:

DANVERS, Mass.–(BUSINESS WIRE)–NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool. The offering provides an on-device, computer-assisted detection (CADe) solution for detecting pulmonary nodules from 10 to 30mm in size through an artificial intelligence (AI) algorithm.*

It is designed to aid the physician in reviewing PA chest radiographs of adults and is part of S-Station, an operation software installed on Samsung Digital X-ray Imaging systems.

“This FDA clearance is a huge milestone for Samsung and is the result of our tireless work to design diagnostic solutions that empower providers to deliver patients the absolute best care possible,” said David Legg, Vice President of Digital Radiography and Ultrasound at Samsung NeuroLogica. “The fact that it delivers clinically reliable results means clinicians can present it to patients with the utmost confidence, and for that we’re very proud.”

Benefits of ALND include:

  • Aiding the reader’s diagnosis by indicating the location of suspected lung nodules on chest X-ray images (posteroanterior chest radiographs). The deep-learning technology has been clinically verified in multiple university hospitals and has been approved with a sensitivity of 80% or more. Investigators at these hospitals – Freiburg University Hospital, Freiburg, Germany; Massachusetts General Hospital, Boston, Massachusetts; Samsung Medical Center, Seoul, South Korea; and Severance Hospital, Seoul, South Korea – retrospectively identified 600 chest radiographs with lung cancer and 200 normal chest radiographs.
  • Extensive external clinical validation that has been recognized by the radiological society for having been performed with ‘unprecedented’ diversity of images acquired under different conditions and demographics, while only producing a small number of false positives per image (0.15).
  • Providing an option (Autorun) to automatically perform nodule detection immediately after chest X-ray imaging, and providing PACS transmission options to suit the hospital environment, both which simplify a user’s workflow.

Clinical evaluation results have demonstrated that all readers’ nodule detection performances using ALND have increased with statistical significance

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?